Keywords: Adherence; Dimethyl fumarate; Diroximel fumarate; Gastrointestinal side effects; Multiple sclerosis; Real-world treatment; Tolerability EN Adherence Dimethyl fumarate Diroximel fumarate Gastrointestinal side effects Multiple sclerosis Real-world treatment Tolerability 2199 2203 5 11/09/23 20231201 NES 231201 This reply refers to the comment available online at https://doi.org/10.1007/s40120-023-00537-x. If we were to change this definition and only include AEs that were documented as being GI related, then the GI-related AE discontinuation rate with DRF would have been lower than what was reported in this analysis. [Extracted from the article]